Company Profile

Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Companyâ€™s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-11-20	Acer Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-11-20	Chris Schelling Ceases to Be Chief Executive Officer of Acer Therapeutics Inc	CI
23-11-20	Harry S. Palmin Ceases to Be Chief Financial Officer of Acer Therapeutics Inc	CI
23-11-20	Acer Therapeutics Inc. Announces Executive Changes	CI
23-11-20	Zevra Therapeutics Completes Acer Acquisition	MT
23-11-16	Zevra Therapeutics, Inc. completed the acquisition of Acer Therapeutics Inc. from funds affiliated with TVM Capital Life Science and others.	CI
23-11-16	Zevra Therapeutics, Inc. completed the acquisition of Acer Therapeutics Inc. from funds affiliated with TVM Capital Life Science and others.	CI
23-11-13	Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index	CI
23-11-08	Acer Therapeutics Inc. - Shareholder/Analyst Call
23-11-08	Acer Therapeutics Inc.(OTCPK:ACER) dropped from NASDAQ Composite Index	CI
23-09-05	HC Wainwright Downgrades Acer Therapeutics to Neutral From Buy	MT
23-09-01	Top Midday Decliners	MT
23-09-01	Roth MKM Downgrades Acer Therapeutics to Neutral From Buy, Price Target is $1.50	MT

23-09-05	HC Wainwright Downgrades Acer Therapeutics to Neutral From Buy	MT
23-09-01	Roth MKM Downgrades Acer Therapeutics to Neutral From Buy, Price Target is $1.50	MT

23-11-02	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals	AQ
23-10-10	ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER	BU
23-09-05	ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER	BU
23-08-31	Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product	AQ
23-08-30	Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe	AQ

23-08-30	Relief Therapeutics conclut un accord de licence avec Acer pour Olpruva
23-08-30	Relief Therapeutics schliesst Lizenz-Abkommen mit Acer für Olpruva
23-05-01	Relief-Partner Acer mit Fortschritten bei Vermarktung von Olpruva
23-04-14	Relief Therapeutics rutscht 2022 tiefer in Verlustzone
23-03-15	Relief-Partner Acer forciert Vermarktung von Olpruva

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-11-16	Jefferson Davis	Issuer sale	CHIEF BUSINESS OFFICER	71,645	0.2929%
23-11-16	Christopher Schelling	Issuer sale	Founder	2,712,529	11.0880%
23-11-16	Donald Joseph	Issuer sale	See Remarks	14,285	0.0584%

Acer Therapeutics Inc. Stock

Stocks

ACER

US00444P1084

Biotechnology & Medical Research

Latest news : Acer Therapeutics Inc.

Analysts' recommendations: Acer Therapeutics Inc.

Press Releases: Acer Therapeutics Inc.

News in other languages: Acer Therapeutics Inc.

Quotes and Performance

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACER THERAPEUTICS INC.	-17.95%	-19.50%	-	-	16.15M
ARGENX SE	+0.33%	+2.83%	+62.37%	+115.97%	55.35B
WUXI APPTEC CO., LTD.	+0.82%	+15.05%	+74.28%	+86.70%	51.92B
BIONTECH SE	-2.10%	+0.83%	-14.33%	-14.96%	22.76B
INSMED INCORPORATED	+0.91%	+5.36%	+2.11%	+421.80%	22.64B
WUXI BIOLOGICS (CAYMAN) INC.	-0.18%	+7.20%	+28.56%	-12.48%	17.36B
GENMAB A/S	-1.10%	+4.61%	+29.38%	-34.99%	16.1B
PHARMAESSENTIA CORPORATION	-3.35%	+8.96%	+135.18%	+294.38%	13.96B
EXELIXIS, INC.	+2.34%	+6.72%	+27.18%	+181.60%	13.38B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.31%	+0.53%	+27.21%	-	12.27B
Average	-1.67%	+4.62%	+41.33%	+129.75%	25.08B
Weighted average by Cap.	+0.26%	+5.29%	+46.88%	+121.29%